---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-048524"
form_type: "8-K"
ticker: "LUDG"
cik: "0001960262"
company_name: "LUDWIG ENTERPRISES, INC."
filed_at: "2025-05-29T23:59:59+00:00"
generated_at: "2026-05-20T06:47:56.781928+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.45
calibrated_materiality_score: 0.45
confidence: "high"
source: SEC EDGAR
---

# Ludwig Enterprises publishes ASCO abstract on non-invasive breast cancer mRNA test

## Summary
- Abstract details mRNA signal from buccal cells combined with machine learning for breast cancer screening.
- Study analyzed 48 mRNA cytokine biomarkers from non-invasive cheek swabs across 40 U.S. clinical centers.
- Top biomarker system achieved F1-score of 0.9, precision 0.892, recall 0.913 (AUC 0.897).
- Second system achieved F1-score of 0.892, precision 0.888, recall 0.902 (AUC 0.849).
- Research presented at ASCO 2025 Annual Meeting; previously under embargo.

## SEC filing metadata
- accession: 0001213900-25-048524
- form_type: 8-K
- ticker: LUDG
- cik: 0001960262
- company_name: LUDWIG ENTERPRISES, INC.
- filed_at: 2025-05-29T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.45
- calibrated_materiality_score: 0.45
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1960262/000121390025048524/0001213900-25-048524-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1960262/000121390025048524/ea0243742-8k_ludwig.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-048524
- JSON: https://secwatch.observer/filing/0001213900-25-048524.json
- Plain text: https://secwatch.observer/filing/0001213900-25-048524.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.